Samsung Securities analyst Keunhee Seo wrote in a report that Samsung Biologics has decided to acquire an American pharmaceutical manufacturer, and this move may increase its new contracts significantly. The South Korean biosimilar contract development and production company has decided to buy 100% of GSK's Rockville, Maryland-based Genome Sciences shares for $280 million. Seo said that this US production site with an annual production capacity of 60,000 liters may enable Samsung Biologics to reach a series of new CDMO agreements with large global pharmaceutical customers who prefer production in the US. He added that the pending Biosafety Act, which aims to make US pharmaceuticals less dependent on the Chinese supply chain, may also help Samsung Biologics secure more new contracts.

Samsung Securities analyst Keunhee Seo wrote in a report that Samsung Biologics has decided to acquire an American pharmaceutical manufacturer, and this move may increase its new contracts significantly. The South Korean biosimilar contract development and production company has decided to buy 100% of GSK's Rockville, Maryland-based Genome Sciences shares for $280 million. Seo said that this US production site with an annual production capacity of 60,000 liters may enable Samsung Biologics to reach a series of new CDMO agreements with large global pharmaceutical customers who prefer production in the US. He added that the pending Biosafety Act, which aims to make US pharmaceuticals less dependent on the Chinese supply chain, may also help Samsung Biologics secure more new contracts.